Hormone supplement
Melatonin
Melatonin after one dose: 50% at ~0.7 h, 25% at 1.4 h, 12.5% at 2.1 h.
Drawn from the half-life in the app's model, ~0.7 h. The model's figures
- Compound
- Melatonin
- Symbol
- MEL
- Family
- Supplements
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
The Circadin product information describes melatonin as a naturally occurring hormone produced by the pineal gland and structurally related to serotonin.2 The European Medicines Agency's product information for Circadin 2 mg prolonged-release tablets lists Circadin as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 or over.2
In the United States, the National Center for Complementary and Integrative Health states that melatonin is considered a dietary supplement, regulated less strictly by the FDA than a prescription or over-the-counter drug would be.3 The same page states that in several other countries melatonin is available only with a prescription and is considered a drug.3 The app grades the evidence for melatonin as strong.
How it works
Sources in this part
The Circadin product information places melatonin in the pharmacotherapeutic group "Psycholeptics, melatonin receptor agonists".2 It states that the activity of melatonin at the MT1, MT2 and MT3 receptors "is believed to contribute to its sleep-promoting properties", and that MT1 and MT2 are mainly involved in regulating circadian rhythms and sleep.2 Dollins and colleagues at the Massachusetts Institute of Technology suggested in 1994 that the physiological increase in serum melatonin around 2100 h each day "may constitute a signal initiating normal sleep onset".4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.7 h
- Bioavailability
- 15%
- Typical dose
- 0.3–5 mg/dose
- Route
- Oral
- Time to peak
- ~0.75 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.7 h (about 42 minutes) | 45 minutes across oral and intravenous routes in a review of 22 studies, with single-study values from 28 to 126 minutes;1 mean 53.7 minutes after 10 mg orally and 39.4 minutes after 10 mg intravenously in 12 men;5 terminal half-life of 3.5 to 4 hours on the Circadin label for a 2 mg prolonged-release tablet2 |
| Bioavailability (oral) | 15% | Approximately 15% with a range of 9 to 33% in the 22-study review;1 approximately 15% for 2 mg and 4 mg oral tablets against 2 mg intravenously in 12 healthy volunteers;6 in the order of 15% on the Circadin label;2 median 2.5% (interquartile range 1.7 to 4.7) for 10 mg orally in 12 men5 |
| Time to peak | ~0.75 h (45 minutes) | Approximately 50 minutes after oral immediate-release formulations in the 22-study review;1 mean 40.8 minutes after 10 mg orally;5 0.75 hours without food against 3.0 hours with food for the 2 mg prolonged-release tablet2 |
| Metabolism and excretion | Not in the app | Liver; experimental data suggest CYP1A1, CYP1A2 and possibly CYP2C19; principal metabolite 6-sulphatoxy-melatonin, called inactive; 89% excreted as conjugates and 2% as unchanged melatonin2 |
The 22-study review by Harpsøe and colleagues (Eur J Clin Pharmacol, 2015) included doses from 0.3 to 100 mg given orally or intravenously.1 It reports that Cmax, AUC, clearance and volume of distribution "varied extensively between studies" and that pharmacokinetics "was affected by age, caffeine, smoking, oral contraceptives, feeding status, and fluvoxamine".1 The Circadin product information states that fluvoxamine increases melatonin levels "by 17-fold higher AUC and a 12-fold higher serum Cmax" and that cigarette smoking may decrease melatonin levels through CYP1A2 induction.2
Deeper analysis: Andersen and colleagues, 2016
Andersen and colleagues at Herlev Hospital, University of Copenhagen, reported a cohort crossover study in BMC Pharmacology and Toxicology in 2016.5 Twelve men aged 20 to 40 years received 10 mg of oral melatonin as a gelatine capsule and 10 mg intravenously on two study days separated by 3 to 9 months.5 Oral melatonin showed a mean time to peak of 40.8 minutes and a mean elimination half-life of 53.7 minutes.5 The authors conclude that bioavailability of oral melatonin "was only 3 %", against the 9 to 33% reported in earlier experimental studies, and that Cmax and AUC "varied extensively between volunteers in both administration routes".5 Their stated limitations include that "this study only included healthy male volunteers in an experimental setup", and that the very low bioavailability "may indicate a deficient absorption of the drug in our setup".5 The paper's competing-interests statement reads "The authors declare that they have no competing interests", and a funding statement was not located in its full text.5
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily, as on the Circadin label2.
An illustration from a pharmacokinetic model using a half-life of 0.7 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Dollins and colleagues, MIT, PNAS 19944 | Double-blind, placebo-controlled, repeated-measure Latin square; NIH grants listed4 | 20 healthy male volunteers4 | 0.1 to 10 mg orally or placebo, given at 1145 h4 | On a simple sleep test at 1330 h (latency and duration of switch release, called indicators of sleep), every dose tested significantly decreased sleep-onset latency and increased sleep duration against placebo; oral temperature also fell4 |
| Zhdanova and colleagues, MIT, J Clin Endocrinol Metab 20017 | Double-blind, placebo-controlled, randomised order; NIH grants listed7 | 30 subjects: 15 who slept normally and 15 with decreased sleep efficiency (insomniac subjects over 50 years old)7 | Placebo and 0.1, 0.3 and 3.0 mg orally 30 min before bedtime, each for a week7 | 0.3 mg restored sleep efficiency (P < 0.0001); 3.0 mg and 0.1 mg also improved sleep, 3.0 mg with hypothermia; control subjects' sleep was unaffected by any dose7 |
| Ferracioli-Oda and colleagues, University of São Paulo, PLoS One 20138 | Meta-analysis of randomised, placebo-controlled trials; partly funded by Eli Lilly awards to the last author8 | 19 studies, 1683 subjects, adults and children with primary sleep disorders8 | Melatonin against placebo; doses and durations varied by trial8 | Sleep latency reduced by 7.06 minutes (95% CI 4.37 to 9.75); total sleep time increased by 8.25 minutes (95% CI 1.74 to 14.75); on objective measures total sleep time changed by 0.33 minutes (95% CI -11.19 to 11.87)8 |
| Herxheimer and Petrie, Cochrane Database of Systematic Reviews 20029 | Systematic review of randomised trials; all 10 compared melatonin with placebo and one also with zolpidem9 | Airline passengers, airline staff or military personnel on flights9 | Oral melatonin, daily doses of 0.5 to 5 mg, taken close to target bedtime at the destination9 | Nine of 10 trials found decreased jet-lag on flights crossing five or more time zones; one trial had a design fault and could not be used; number needed to treat of 2; the review notes the relative ineffectiveness of 2mg slow-release melatonin, and that a dose taken at the wrong time, early in the day, is liable to cause sleepiness and delay adaptation to local time9 |
| Maruani and colleagues, J Sleep Res 202310 | Systematic review and meta-analysis against placebo; funding not stated in the record read10 | 22 studies, 4875 participants with insomnia disorder: 925 on melatonin, 1804 on ramelteon, 2297 on placebo10 | Mostly acute-phase studies of prolonged-release melatonin10 | Prolonged-release melatonin: subjective sleep onset latency -6.30 min (p = 0.031), objective -5.05 min (p < 0.001), objective sleep efficiency +1.91% (p = 0.043)10 |
| Cruz-Sanabria and colleagues, J Pineal Res 202411 | Systematic review and dose-response meta-analysis of double-blind randomised trials; grants from Fondazione Arpa and the Italian Ministry of Health11 | 26 trials published 1987 to 2020, 1689 observations, patients with insomnia and healthy volunteers11 | Dose-response modelling of sleep onset latency and total sleep time against placebo11 | Melatonin gradually reduced sleep onset latency and increased total sleep time, peaking at 4 mg/day11 |
| Circadin product information, studies in primary insomnia (EMA)2 | Placebo-controlled, parallel group, 3-week double-blind periods; one 6-month study re-randomised at 3 weeks (n=600); sponsor not named in the text read2 | Patients with primary insomnia; label indication is age 55 or over2 | Circadin 2 mg every evening for 3 weeks2 | Sleep latency shortened by 9 minutes against placebo (polysomnography); responders 47% against 27% and 26% against 15% (two outpatient studies); in the n=600 study the benefit held to 3 months but failed the primary analysis set at 6 months2 |
| Circadin product information, paediatric study (EMA)2 | Randomised, double-blind, placebo-controlled, 13 weeks2 | Paediatric population, n=1252 | 2, 5 or 10 mg prolonged-release, 13 weeks2 | Total sleep time 508 against 488 minutes; sleep latency 61 against 77 minutes; dropouts 9 patients (15.0%) on active treatment against 21 (32.3%) on placebo; treatment emergent adverse events 85% against 77%2 |
Deeper analysis: Dollins and colleagues, 1994
Dollins and colleagues (Massachusetts Institute of Technology) gave "very low doses of melatonin (0.1-10 mg, orally) or placebo" at 1145 h to 20 healthy male volunteers in a double-blind Latin square design.4 Areas under the concentration curve rose in proportion to dose, and the 0.1 and 0.3 mg doses "generated peak serum melatonin levels that were within the normal range of nocturnal melatonin levels in untreated people".4 The authors also report that all doses significantly increased self-reported sleepiness and fatigue and decreased correct responses on an auditory vigilance task.4 The paper's grants are from NIH institutes, and the text read contains no author-disclosure statement or statement of limitations; the participants were men and the doses were given at midday, not at bedtime.4
Deeper analysis: Zhdanova and colleagues, 2001
Zhdanova and colleagues (Massachusetts Institute of Technology; Wurtman is a co-author) reported in 2001 a double-blind, placebo-controlled trial of three oral doses in 15 insomniac subjects over 50 years old and 15 subjects who slept normally.7 In the insomniac group the 0.3 mg dose restored sleep efficiency "acting principally in the midthird of the night" and elevated plasma melatonin to normal (P < 0.0008).7 The 3.0 mg dose "induced hypothermia and caused plasma melatonin to remain elevated into the daylight hours", while sleep in control subjects "was unaffected by any melatonin dose".7 The record lists NIH grants (NCRR, NIA) and no industry sponsor, and contains no limitations statement or author-disclosure statement.7
Deeper analysis: Ferracioli-Oda and colleagues, 2013
Ferracioli-Oda, Qawasmi and Bloch (University of São Paulo and collaborators) searched PubMed for randomised, placebo-controlled trials of melatonin in primary sleep disorders and pooled 19 studies with 1683 subjects, of which 14 were in insomnia, 4 in delayed sleep phase syndrome and 1 in REM sleep behavior disorder.8 Sleep latency fell by 7.06 minutes (95% CI 4.37 to 9.75) and total sleep time rose by 8.25 minutes (95% CI 1.74 to 14.75), with significant heterogeneity for sleep latency (I2 = 56%).8 In the random-effects model for total sleep time the estimate was 8.48 minutes with a 95% CI of -4.02 to 20.98 (p = 0.184), and on objective measures total sleep time did not differ significantly (0.33 minutes, 95% CI -11.19 to 11.87).8 Meta-regression found that "trials with longer duration and using higher doses of melatonin demonstrated greater effects on decreasing sleep latency and increasing total sleep time", although the dose effect on sleep latency was at trend levels (p = 0.05) and no significant effects of trial duration or dose were observed on sleep quality.8 The authors call the effects "modest" and write that the absolute benefit "is smaller than other pharmacological treatments for insomnia".8 Their stated limitations include that "our meta-regression analysis had limited power", that "one trial contributed a very large weight to our overall findings", and that few studies in children "precluded any stratified subgroup analysis based on age".8 The study was "partly funded by APIRE/Eli Lilly Psychiatric Research Fellowship (to MHB) and the AACAP/Eli Lilly Pilot Research Award (to MHB)".8
Deeper analysis: Herxheimer and Petrie, Cochrane review, 2002
Herxheimer and Petrie (UK Cochrane Centre) searched the Cochrane Controlled Trials Register, MEDLINE, EMBASE, PsychLit and Science Citation Index, and included ten randomised trials, nine of them of adequate quality to contribute to the assessment.9 They report that doses of 0.5 to 5 mg daily "are similarly effective, except that people fall asleep faster and sleep better after 5mg than 0.5mg", and that doses above 5 mg "appear to be no more effective".9 The review adds that the "relative ineffectiveness of 2mg slow-release melatonin suggests that a short-lived higher peak concentration of melatonin works better".9 The review states that a dose taken at the wrong time, early in the day, "is liable to cause sleepiness and delay adaptation to local time", and that "the incidence of other side effects is low".9 It adds that "case reports suggest that people with epilepsy, and patients taking warfarin may come to harm from melatonin".9 The PubMed record read gives no funding statement, limitations section or author-disclosure statement.9
Deeper analysis: Maruani and colleagues, 2023
Maruani and colleagues (Hôpital Bichat-Claude Bernard, Paris, and University of Strasbourg) begin by noting that "Melatonin has gained growing interest as a treatment of insomnia, despite contradictory findings, and a low level of evidence".10 Against placebo, prolonged-release melatonin showed a "small to medium effect size" on subjective sleep onset latency (-6.30 min, p = 0.031), objective sleep onset latency (-5.05 min, p < 0.001) and objective sleep efficiency (+1.91%, p = 0.043).10 For the subgroup with a mean age of 55 or over, prolonged-release melatonin was efficacious on objective sleep efficiency with a "large effect size" (+2.95%, p < 0.001).10 The PubMed record read contains no funding statement, no limitations statement and no author-disclosure statement, and the review states that most studies evaluated the acute efficacy of prolonged-release melatonin.10
Deeper analysis: Cruz-Sanabria and colleagues, 2024
Cruz-Sanabria and colleagues (IRCCS Fondazione Stella Maris, Pisa) pooled 26 double-blind randomised trials in patients with insomnia and healthy volunteers.11 Dose-response meta-analysis showed that melatonin "gradually reduces sleep onset latency and increases total sleep time, peaking at 4 mg/day".11 The authors describe "2 mg 30 min before the desired bedtime" as the schedule most used in clinical practice.11 The grants listed are from Fondazione Arpa and the Italian Ministry of Health, and the PubMed record read contains no limitations statement or author-disclosure statement.11
Doses reported in studies and on labels
| Source | Dose and route | Comparator, duration and n |
|---|---|---|
| Circadin label, patients aged 55 or over with primary insomnia2 | 2 mg prolonged-release tablet once daily, 1-2 hours before bedtime and after food, by mouth2 | Up to thirteen weeks on the label; placebo-controlled studies ran 3 weeks2 |
| Dollins 19944 | 0.1 to 10 mg orally at 1145 h4 | Placebo, Latin square, 20 healthy men4 |
| Zhdanova 20017 | 0.1, 0.3 and 3.0 mg orally 30 min before bedtime7 | Placebo, one week per treatment with 1-week washouts, 30 subjects7 |
| Herxheimer and Petrie 20029 | 0.5 to 5 mg daily by mouth, close to target bedtime at the destination9 | Placebo; 10 randomised trials in travellers9 |
The app lists a typical range of 0.3 to 5 mg per dose, and its notes cite Wurtman group data in which 0.3 to 0.5 mg outperforms 5 to 10 mg. In the sources read, Dollins and colleagues report that every dose from 0.1 to 10 mg differed from placebo, Zhdanova and colleagues report that 3.0 mg also improved sleep but induced hypothermia, and Herxheimer and Petrie report faster sleep after 5 mg than 0.5 mg.4,7,9 None of these records states that 0.3 to 0.5 mg outperforms 5 to 10 mg for sleep onset.4,7,9
Side effects reported
In the clinical trials summarised in the Circadin product information, 1,931 patients took Circadin and 1,642 took placebo, and 48.8% of those on Circadin reported an adverse reaction compared with 37.8% on placebo.2 Per 100 patient weeks the rate was 3.013 on Circadin and 5.743 on placebo, and the most common adverse reactions, headache, nasopharyngitis, back pain and arthralgia, occurred in both groups.2 The label also states that "Circadin may cause drowsiness".2 In its paediatric study, nervous system disorders were reported by 42% of the active group and 23% of the placebo group, "mainly driven by somnolence and headache".2
Deeper analysis: Besag and colleagues, 2019
Besag and colleagues (CNS Drugs, 2019) searched PubMed/Medline and Google Scholar for randomised, placebo-controlled trials of exogenous melatonin in primary or secondary sleep disorders and included 37 trials with daily doses of 0.15 mg to 12 mg.12 The most frequently reported adverse events were daytime sleepiness (1.66%), headache (0.74%), other sleep-related adverse events (0.74%), dizziness (0.74%) and hypothermia (0.62%).12 The authors report that "Very few AEs considered to be serious or of clinical significance were reported", naming agitation, fatigue, mood swings, nightmares, skin irritation and palpitations, and conclude that "Few, generally mild to moderate, AEs were associated with exogenous melatonin".12 Their stated limitations are that subjects were monitored for up to 29 weeks but most studies lasted 4 weeks or less, that "only eight studies were judged 'good' overall" on risk of bias, and that "the scarcity of evidence from long-term RCTs" limits conclusions about continuous use.12 The PubMed record read gives no funding statement or author-disclosure statement.12
Deeper analysis: Händel and colleagues, 2023 (children and adolescents)
Händel and colleagues reported in EClinicalMedicine in 2023 a systematic review of melatonin in children and adolescents aged 5 to 20 years with chronic insomnia, using GRADE.13 It identified "22 randomised studies with 1350 patients" reporting on serious and non-serious adverse events and four observational studies with 105 patients reporting on pubertal development.13 Melatonin "was not associated with serious adverse events, yet the number of patients experiencing non-serious adverse events was increased (Relative risk 1.56, 95% CI 1.01-2.43, 17 studies, I2 = 47%)".13 Three observational studies reported little or no influence on pubertal development after 2 to 4 years, and one a potential delay after more than 7 years.13 The authors rate certainty for adverse events in randomised studies as moderate because of "an imprecise effect estimate (wide confidence interval)" and certainty for the long-term observational outcomes as very low because of serious risk of bias.13 They write that the extent of non-serious adverse events and "the long-term consequences remain uncertain", and that adverse events "may be underreported and/or insufficiently investigated".13 The review was funded by the Danish Health Authority and the Parker Institute, supported by the Oak Foundation, and its conflict-of-interest statement lists, for one author, honoraria from AGB pharma, Takeda and Medice and stocks at Novo Nordisk.13
Product contents and poison-centre reports
Cohen and colleagues (Cambridge Health Alliance and University of Mississippi) reported in JAMA in 2023 an analysis of 25 products sold as melatonin gummies, bought online after being listed in the NIH Dietary Supplement Label Database.14 One product had no detectable melatonin but contained 31.3 mg of CBD, and "Twenty-two of 25 products (88%) were inaccurately labeled", with melatonin from 74% to 347% of the labeled quantity.14 The authors name as limitations that "the sample size was small, only 1 sample of each brand was analyzed, and only gummies were analyzed".14 Dr Cohen reported research support from Consumers Union and PEW Charitable Trusts and royalties from UptoDate, and that he was the subject of a civil suit brought by Hi-Tech Pharmaceuticals, a supplement company, in which the jury found in his favor; Dr Khan reported grants from the FDA, the National Institutes of Health and the US Department of Agriculture and coordinates a conference that receives support for conference-related expenses from multiple supplement-related companies; the letter's text read contains no separate funding statement.14
NCCIH states that there is not enough information yet about possible side effects of melatonin supplements, particularly at doses higher than what the body normally produces, to have a clear picture of overall safety, and that short-term use "appears to be safe for most people, but information on the long-term safety of supplementing with melatonin is lacking".3 NCCIH reports that poison control centre reports about people 19 years and younger rose from 8,337 in 2012 to 52,563 in 2021; of 4,097 people hospitalized over the 10 years, 287 needed intensive care, five required mechanical ventilation and two children younger than age 2 died, but the data "did not show whether the two deaths were caused by a melatonin overdose or another cause".3
Regulatory and anti-doping status
In the EU, Circadin 2 mg prolonged-release tablets were first authorised on 29 June 2007 for short-term treatment of primary insomnia in patients aged 55 or over.2 Besag and colleagues state that melatonin "has also recently been licensed in the UK for the short-term treatment of jetlag".12 In the United States, Cohen and colleagues state that "Melatonin products are not approved by the US Food and Drug Administration (FDA)" and are sold over the counter as dietary supplements or food.14 Melatonin is not named in the text of the 2026 WADA Prohibited List that was searched; a text search for "melatonin" returned no match.15 That search does not show how any general class on the list applies to a specific product.
Storage and handling
Sources in this part
The Circadin label states a shelf life of 3 years and, for the 2 mg tablet, "Do not store above 25°C. Store in the original package in order to protect from light."2
What is not known
The Circadin product information states that the safety and efficacy of Circadin in children aged 0 to 18 years "has not yet been established" and that for pregnancy "no clinical data on exposed pregnancies are available".2 NCCIH states that there has been "a lack of research on the safety of melatonin use in pregnant or breastfeeding women".3 On efficacy, the 2023 insomnia meta-analysis refers to "contradictory findings, and a low level of evidence", and the Circadin 6-month study "failed the primary analysis set at 6 months".10,2 Sources differ on oral bioavailability (about 15% against a median of 2.5%) and on half-life (45 minutes in the 22-study review and 53.7 minutes after 10 mg orally in one study, against 3.5 to 4 hours on the label for a 2 mg prolonged-release tablet), so the app's single figures are one reading among several.1,5,2
Frequently asked questions
What is the half-life of melatonin?
What is the bioavailability of oral melatonin?
How long does melatonin take to reach its peak level?
Is melatonin banned by WADA?
Melatonin is not named in the text of the 2026 WADA Prohibited List that was searched.15
Is melatonin a prescription medicine?
In the United States it is considered a dietary supplement, and NCCIH states that in several other countries it is available only with a prescription and is considered a drug.3
What did the 2013 meta-analysis of melatonin for sleep find?
It reported a reduction in sleep latency of 7.06 minutes (95% CI 4.37 to 9.75) and an increase in total sleep time of 8.25 minutes (95% CI 1.74 to 14.75) against placebo in 19 studies.8 On objective measures total sleep time did not differ significantly (0.33 minutes, 95% CI -11.19 to 11.87), and in the random-effects model the total sleep time estimate was 8.48 minutes (95% CI -4.02 to 20.98, p = 0.184).8 The authors describe the effects of melatonin on sleep as modest.8
Do melatonin gummy labels match what the products contain?
In a 2023 JAMA analysis of 25 gummy products, 22 (88%) were inaccurately labeled.14
What side effects of melatonin are reported?
In the Circadin trials, the most common adverse reactions were headache, nasopharyngitis, back pain and arthralgia, in both the Circadin and placebo groups.2 A systematic review of 37 randomised trials reported daytime sleepiness (1.66%) and headache (0.74%) among the most frequently reported adverse events.12
Guides, tools and comparisons
References
- Harpsøe NG, et al. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol 2015. PMID 26008214
- European Medicines Agency. Circadin 2 mg prolonged-release tablets: summary of product characteristics (EPAR product information). EMA product information
- National Center for Complementary and Integrative Health. Melatonin: What You Need To Know. NCCIH page
- Dollins AB, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA 1994. PMID 8127888
- Andersen LP, et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol 2016. PMID 26893170
- DeMuro RL, et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000. PMID 10883420
- Zhdanova IV, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001. PMID 11600532
- Ferracioli-Oda E, et al. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013. PMID 23691095
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002. PMID 12076414
- Maruani J, et al. Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: a systematic review and meta-analysis. J Sleep Res 2023. PMID 37434463
- Cruz-Sanabria F, et al. Optimizing the time and dose of melatonin as a sleep-promoting drug: a systematic review of randomized controlled trials and dose-response meta-analysis. J Pineal Res 2024. PMID 38888087
- Besag FMC, et al. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs 2019. PMID 31722088
- Händel MN, et al. The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessment. EClinicalMedicine 2023. PMID 37483551
- Cohen PA, et al. Quantity of melatonin and CBD in melatonin gummies sold in the US. JAMA 2023. PMID 37097362
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list